Search research articles
Contact Us
Filters
Showing results (301-310 of 491) with videos related to
Page
of 50
Sort By:
Melanoma Research
|
April 4, 2023
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment
Bożena Cybulska-Stopa, Karolina Piejko, Krzysztof Ostaszewski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Biomed Research International
|
February 25, 2021
Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs
Ewa Paszkiewicz-Kozik, Agnieszka Paziewska, Maria Kulecka, et al.
The Lancet. Oncology
|
December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Paolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
July 17, 2007
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors
Jerzy Lasota, Anna Jerzak vel Dobosz, Bartosz Wasag, et al.
Eclinicalmedicine
|
September 21, 2023
An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: an observational cohort study
Dimitris Bertsimas, Georgios Antonios Margonis, Seehanah Tang, et al.
Cells
|
February 13, 2021
Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis
Mateusz Jacek Spałek, Jan Poleszczuk, Anna Małgorzata Czarnecka, et al.
Melanoma Research
|
May 22, 2018
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors
Paweł Teterycz, Paulina Jagodzińska-Mucha, Bożena Cybulska-Stopa, et al.
Page
of 50
Search research articles
Search
Showing results (301-310 of 491) with videos related to
Sort By:
Page
of 50
Melanoma Research
|
April 4, 2023
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment
Bożena Cybulska-Stopa, Karolina Piejko, Krzysztof Ostaszewski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schöffski, Agnieszka Wozniak, Bernard Escudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Biomed Research International
|
February 25, 2021
Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs
Ewa Paszkiewicz-Kozik, Agnieszka Paziewska, Maria Kulecka, et al.
The Lancet. Oncology
|
December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Paolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
July 17, 2007
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors
Jerzy Lasota, Anna Jerzak vel Dobosz, Bartosz Wasag, et al.
Eclinicalmedicine
|
September 21, 2023
An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: an observational cohort study
Dimitris Bertsimas, Georgios Antonios Margonis, Seehanah Tang, et al.
Cells
|
February 13, 2021
Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis
Mateusz Jacek Spałek, Jan Poleszczuk, Anna Małgorzata Czarnecka, et al.
Melanoma Research
|
May 22, 2018
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors
Paweł Teterycz, Paulina Jagodzińska-Mucha, Bożena Cybulska-Stopa, et al.
Page
of 50